Andrew Sochacki, MD
Hematology & Oncology · Grand Rapids, MINPI 1003235391
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 66 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$195
- Bristol Myers Squibb$183
- E.r. Squibb & Sons, L.L.C.$99
- Novartis$94
- Johnson & Johnson$92
- Genentech USA, Inc.$85
- plus $612 from 19 others
Across 319 payments — averaging $4313.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$392K
- Janssen Research & Development, LLC$351K
- Incyte Corporation$211K
- Boehringer Ingelheim$163K
- Bristol Myers Squibb$141K
- GSK$86K
- plus $32K from 3 others
What the payments were for
- Food & beverage$1,33098%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 9 | $195 |
| Bristol Myers Squibb | 10 | $183 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Novartis | 5 | $94 |
| Johnson & Johnson | 3 | $92 |
| Genentech USA, Inc. | 4 | $85 |
| Sanofi | 3 | $79 |
| Gilead | 3 | $62 |
| Pfizer | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Beigene USA, Inc. | 2 | $45 |
| Amgen | 2 | $44 |
| AstraZeneca | 2 | $34 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $31 |
| Merck | 1 | $31 |
| GSK | 1 | $25 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Genmab U.S., Inc. | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$1,360 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 181 | $3,241,555 |
| Lenalidomide | 165 | $2,416,680 |
| ImbruvicaIbrutinib | 116 | $1,718,961 |
| CalquenceAcalabrutinib Maleate | 128 | $1,694,684 |
| VenclextaVenetoclax | 108 | $996,210 |
| PomalystPomalidomide | 42 | $934,372 |
| OjjaaraMomelotinib Dihydrochloride | 16 | $436,827 |
| IdhifaEnasidenib Mesylate | 11 | $424,150 |
| BrukinsaZanubrutinib | 29 | $418,836 |
| JakafiRuxolitinib Phosphate | 22 | $370,652 |
| NeulastaPegfilgrastim | 49 | $308,188 |
| SprycelDasatinib | 18 | $282,762 |
| NyvepriaPegfilgrastim-Apgf | 44 | $164,388 |
| EliquisApixaban | 188 | $120,035 |
| Imatinib Mesylate | 48 | $63,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Idhifa | $183 | $3,665,706192 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $195 | $1,718,961116 claims |
| AstraZenecaCalquence | $34 | $1,694,684128 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $99 | $1,217,13460 claims |
| AbbVieVenclexta | $16 | $996,210108 claims |
| GSKOjjaara | $25 | $436,82716 claims |
| Beigene USA, Inc.Brukinsa | $45 | $418,83629 claims |
| AmgenNeulasta | $44 | $308,18849 claims |
| PfizerNyvepria, Eliquis | $48 | $284,424232 claims |
| Johnson & JohnsonXarelto | $92 | $26,98943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$305K
- Nehal LakhaniGrand Rapids$13K
- Eric SantosGrand Rapids$11K
- Erin PettijohnGrand Rapids$10K
- Colin HardinGrand Rapids$10K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.